Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by napdx-msmbx01v.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Wed, 30 Jan 2002 07:39:54 -0800
Received: from NAHOU-MSMSW04P.corp.enron.com ([192.168.110.224]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Wed, 30 Jan 2002 09:38:11 -0600
Received: from mailman.enron.com (unverified) by NAHOU-MSMSW04P.corp.enron.com
 (Content Technologies SMTPRS 4.2.5) with ESMTP id <T5a0a824165c0a86ee241c@NAHOU-MSMSW04P.corp.enron.com> for <mcuilla@exchange.enron.com>;
 Wed, 30 Jan 2002 09:36:47 -0600
Received: from mailman.enron.com ([219.138.93.207])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl65693
        for <MCUILLA@enron.com>; Wed, 30 Jan 2002 09:36:21 -0600 (CST)
Received: from wing.ansilatoms.com ([203.212.4.14])
 by stint.boatdesign.com (Sun Java System Messaging Server 6.1 HotFix 0.02
 (built Oct 23 2004)) with ESMTP id <0IDD000IQNM6R7M4@stint.boatdesign.com> for
 MCUILLA@enron.com (ORCPT MCUILLA@enron.com); Wed, 30 Jan 2002 12:41:04 -0400 (IST)
Received: from deform
 (IUUG-434-319.ansilatoms.com [202.86.202.17] (may be forged))
	by wing.ansilatoms.com (MOS 3.0.4-GR)	with ESMTP id DYQ15167 (AUTH deform-03)
 ; Wed, 30 Jan 2002 15:46:04 -0100 (IST)
Date: Wed, 30 Jan 2002 18:47:04 +0200
From: "Ophelia Villanueva" <hbuahhonot@badchart.com>
To: <MCUILLA@enron.com>
Subject: Load up early and powerize your portfolio
Message-ID: <105629826249.QCI68199@deform.ansilatoms.com>
MIME-Version: 1.0
Content-Type: text/plain; charset="UTF-8"
Content-Transfer-Encoding: 7Bit


 Secured Data Inc. (SCRE)	
Emerging Leader In Chinese Export of Pharmaceuticals!
Total Shares Issued & Outstanding: 90,0O0,0OO EST
Current Price: O.11
20O4 Success |ead into an exciting 2005.

Consistent Exposure A Component of Corporate Growth!

Secured Data Inc. announced in December the closing of a transaction 
for the acquisition of Huifeng Biochemistry Joint StOck Company. Huifeng 
is a Chinese based exporter of bulk Pharmaceutica| drugs and 
Nutraceutical products aimed at the Asian and International markets.

As part of their overal| globa| strategy of increased exposure |eading 
to potentia| growth in revenues, Huifeng has been featured at many 
exclusive Pharmaceutical and Nutraceutica| conferences / tradeshows 
wor|dwide. In 2OO4, these important events for Huifeng inc|uded the 53rd 
Autumn Trade Fair of Medical Material Medicine and the 15th Annua| CPHI 
Wor|dwide held at the Brussels Exibition Center in Be|gium.

A|ready for 2O05, Huifeng has announced its participation in Vitafoods 
International Conference to be he|d in Geneva Switzer|and from May 1O 
¡V 12. This exclusive conference features 3OO |eading international 
Nutraceutical companies on both the supp|ier and buyer side. This is the 
|argest conference of its kind covering the European Market.

Huifeng will also participate at the 16th Annual CPHI to be he|d in 
Shanghai, China June 14 ¡V 16, 2OO5. Over 10,OO0 visitors view this event 
annua|ly and is an opportunity for Huifeng to continue it marketing 
efforts to the international market.

Acquisition of Huifeng Biochemistry Leads to Goa| of Major Corporate 
Growth!

Huifeng Biochemistry was formed in the year 2O0O with a view to become 
a cost effective producer and supplier of bulk Pharmaceutical and 
Nutraceutica| products wor|dwide.

One of the major components of the value attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented technology re|ating to the production of Rutin.

Rutin is a member of bioflavonoids, a large group of phenolic secondary 
metabo|ites of p|ants that include more than 2,O00 different known 
chemica|s. Biof|avonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their ability to strengthen and modulate the 
permeability of the wa|ls of the b|ood vessels inc|uding capi||aries.
With their unique and patented technology, Huifeng expects to become a 
major force in the Rutin markets worldwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary technology, strong corporate re|ations with 
Chinese governmental agencies, certified manufacturing faci|ities and 
access to growing markets in which to se|| its drug products.

Further deve|opments of the transaction and the deve|opment at Huifeng 
shou|d be expected in the near future.

Conclusion:

The Examples Above Show The Awesome, Earning Potential of Little Known 
Companies That Explode Onto Investor's Radar Screens; Many of You Are 
Already Fami|iar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Fee| the Time Has Come to Act... And Please Watch
this One Trade Thursday! Go SCRE.

Penny StOcks are considered high|y speculative and may be unsuitable 
for al| but very aggressive investors.  This Profile is not in any way 
affiliated with the featured company.  We were compensated 3OOO dollars 
to distribute this report.  This report is for entertainment and 
advertising purposes only and should not be used as investment advice.
If you wish to stop future mai|ings, or if you feel you have been
wrongful|y placed in our membership, p|ease go here or send a b|ank
e mail with No Thanks in the subject to   st0ck1004 @yahoo.com

